The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon

Journal of Infectious Diseases

Volumn 182, Issue 2, 2000, Pages 397-404

  Polyak, Stephen J ^a   Nousbaum, Jean Baptiste ^a,c   Larson, Anne M ^a   Cotler, Scott ^b   Carithers, Robert L ^a   Gretch, David R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DOUBLE STRANDED RNA; INTERFERON; PROTEIN KINASE; VIRUS GLYCOPROTEIN; VIRUS RNA;

AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS ENVELOPE; VIRUS HEPATITIS; VIRUS ISOLATION;

AMINO ACID SEQUENCE; BINDING SITES; CONSERVED SEQUENCE; EIF-2 KINASE; EUKARYOTIC INITIATION FACTOR-2; GENOTYPE; GLYCOPROTEINS; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SEQUENCE HOMOLOGY, AMINO ACID; VIRAL ENVELOPE PROTEINS;

EID: 0033837013     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315720     Document Type: Article

References (44)

1. Public health service interagency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C
2. Projecting the future health care burden from hepatitis C in the United States
3. Pathogenesis, natural history, treatment, and prevention of hepatitis C
4. Therapy of hepatitis C: Overview
5. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
6. Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials
7. Pretreatment viral load and response to prolonged interferon-α course for chronic hepatitis C
8. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis
9. Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C
10. High sustained response rate and clearance of viraemia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks
11. Interferon alfa-2b for chronic hepatitis C: Effects of dose increment and duration of treatment on response rates
12. Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: A 4-year follow-up of 211 patients
13. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa
14. Higher dose interferon therapy increases end-of-treatment virological response in patients with chronic hepatitis C
15. An escalating dose regime of recombinant interferon alpha 2A in the treatment of chronic hepatitis C
16. High dose interferon treatment in chronic hepatitis C
17. Treatment of chronic hepatitis C with highdose interferon α-2b: A multicenter study
18. Induction dosing with interferon 2b: An international study
19. Long term efficacy of induction IFN therapy for 4 weeks followed by a standard TIW schedule in chronic hepatitis C
20. The importance of initial daily administration of interferon alpha for the eradication of hepatitis C virus in patients with chronic hepatitis C: A multicenter randomized trial
21. Four weeks of daily therapy with IFN 2b + ribavirin followed by standard therapy in genotype 3: Results at 12 weeks
22. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C
23. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C
24. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C
25. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C
26. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience
27. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
28. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
29. Quasispecies in viral persistence and pathogenesis of hepatitis C virus
30. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: A potential mechanism of interferon resistance
31. Mutations in the nonstructural protein 5A and response to interferon in patients with chronic hepatitis C virus 1b infection
32. The molecular basis for responsiveness to anti-viral therapy in hepatitis C
33. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein
34. Assessment of hepatitis C viremia using molecular amplification technologies: Correlations and clinical implications
35. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5' non-coding region
36. Prospective characterization of full-length HCV NS5A quasispecies during induction and combination antiviral therapy
37. Hepatitis C virus, the E2 envelope protein, and the alpha-interferon response
38. Evolution of hepatitis C virus quasi-species in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection
39. Comparison of full-length sequences of interferon-sensitive and -resistant hepatitis C virus 1b: Sensitivity to interferon is conferred by amino acid substitutions in the NSSA gene
40. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C
41. Assessment of hepatitis C virus quasispecies heterogeneity by gel shift analysis: Correlation with response to Interferon therapy
42. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): Influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C
43. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line